Continuous control of intraocular pressure (IOP) is crucial to preventing long-term damage to the optic nerve in glaucoma. Recently, a novel telemetric IOP sensor (EYEMATE-IO™, Implandata Ophthalmic Products GmbH, Hannover, Germany) has been developed that continuously records IOP. The patient can read the IOP measurements wirelessly using a hand-held reading device. We present the case of a 70-year-old patient with primary open-angle glaucoma who had been implanted with an EYEMATE-IO™ and recently underwent minimally invasive bleb-filtering surgery with the PreserFlo MicroShunt (Santen, Osaka, Japan). This case demonstrates both the benefits of continuous pressure measurement with EYEMATE-IO™ and the ability of the PreserFlo MicroShunt to significantly reduce IOP fluctuations.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875318 | PMC |
| http://dx.doi.org/10.1177/25158414221149927 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Xen 63 versus Preserflo MicroShunt implant in patients with primary open-angle glaucoma.
Sci Rep
January 2025
Department of Ophthalmology and ORL, Faculty of Medicine, Clinico San Carlos Hospital, Complutense University, Clinico San Carlos Hospital Health Research Institute (IdISSC), Calle del Prof Martín Lagos, s/n,, Madrid, 28040, Spain.
This study compared the efficacy safety profiles of the Xen 63 and Preserflo MicroShunt devices, both standalone, in patients with primary open-angle glaucoma (POAG). It is a retrospective and single-center study conducted on consecutive on patients with medically uncontrolled POAG who underwent either a standalone Xen 63 or a standalone Preserflo and had a 12-month follow-up visit. The primary outcome was the mean IOP at month-12.
View Article and Find Full Text PDFIntraluminal Insertion of 9-0 Nylon for Postoperative Choroidal Detachment After Preserflo MicroShunt Implantation: A Case Report.
Cureus
November 2024
Department of Ophthalmology and Visual Science, Chiba University Graduate School of Medicine, Chiba, JPN.
Preserflo MicroShunt (PMS) implantation is a minimally invasive surgical procedure for treating glaucoma. Postoperative hypotony, a common complication of PMS implantation, can be prevented and treated with 10-0 nylon insertion. In this report, we present a case of postoperative hypotony following PMS implantation that was treated with intraluminal insertion of 9-0 nylon.
View Article and Find Full Text PDFPreserflo MicroShunt Implantation for Glaucoma Secondary to Viral and Juvenile Idiopathic Arthritis-Related Anterior Uveitis.
Ocul Immunol Inflamm
December 2024
Centre for Ophthalmology, University Hospital Tuebingen, Tuebingen, Germany.
Purpose: To investigate the efficacy and safety of the Preserflo MicroShunt (PMS) in treating glaucoma secondary to different uveitic glaucoma (UG) types in a European population.
Methods: This study evaluated consecutive eyes with UG that received the PMS. The primary outcome measure was 12-month surgical success (≥20% IOP reduction, target IOP of 6-21 mmHg).
Preserflo MicroShunt Implantation: A Narrative Review of Its Standalone Benefits vs. Combined Use with Phacoemulsification in Managing Open-Angle Glaucoma.
Ophthalmol Ther
January 2025
Department of Ophthalmology, Medical University of Bialystok, M. Sklodowskiej-Curie 24 A STR, 15-276, Bialystok, Poland.
Glaucoma and cataract often coexist. Patients with both conditions who qualify for surgical treatment may undergo either a combined surgical procedure or sequential treatments such as cataract surgery followed by an antiglaucoma procedure. A combined procedure with phacoemulsification is related to an increased risk of fibrosis of the filtering bleb; however, it is a rational approach for patients with high intraocular pressure and clinically significant lens opacification.
View Article and Find Full Text PDFAnterior Segment Optical Coherence Tomography (AS-OCT) 3D Observation of PreserFlo MicroShunt.
Cureus
October 2024
Department of Ophthalmology, Shimane University Faculty of Medicine, Izumo, JPN.
A 74-year-old Japanese woman with a history of primary open-angle glaucoma (POAG) in both eyes underwent PreserFlo MicroShunt (PFM) (Osaka, Japan: Santen Pharmaceutical, Co., Ltd.) implantation two years prior.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!